Logo

American Heart Association

  13
  0


Final ID: MDP1290

Sex Influences Effects on Atherosclerosis in TET2-related Clonal Hematopoiesis of Indeterminate Potential and on Interleukin-1β Inhibition in Mice

Abstract Body (Do not enter title and authors here): Background: Clonal hematopoiesis of indeterminate potential (CHIP) refers to somatic mutations in hematopoietic cells with a minimum allele fraction ≥ 2% without hematological disease. CHIP depends on age and increases the risk of coronary artery disease (CAD). In their 70s women’s prevalence of cardiovascular disease catches up to that of men. In Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) neutralizing interleukin-1β (IL-1β) in chronic CAD, subjects with TET2 CHIP showed greater reduction of cardiovascular events. However, this substudy did not investigate sex.

Hypothesis: We hypothesized that sex modifies the association between CHIP mutations and risk of CAD, and the effects of IL-1β inhibition in CHIP-related atherosclerosis in mice.

Methods: Sex differences on the association of CAD and CHIP mutations were investigated using 2 cohorts: the UK and Mass General Brigham Biobanks. CHIP genes showing sex differences in human data were deleted in hematopoietic cells of female and male atherosclerosis-susceptible Ldlr-/- mice. Mice consumed a 0.2% cholesterol high-fat diet with or without an anti-mouse IL-1β monoclonal antibody for 9 weeks. We assessed atherosclerosis by histology and performed mechanistic studies using single-cell RNA sequencing (scRNAseq) of atherosclerotic aortic arch and in vitro bone-marrow derived macrophages.

Results: Women with TET2 CHIP had larger hazard ratio for CAD than men in both biobanks. Overall CHIP and other mutations did not demonstrate sex differences in the association with CAD. In Ldlr-/- mice deficient for Tet2 in hematopoietic cells, IL-1β inhibition reduced atherosclerosis in female but not male mice. ScRNAseq revealed more inflammatory cells and more expression of inflammatory genes in hematopoietic Tet2-/- females than in males. IL-1β inhibition limited these sex differences. In vitro experiments demonstrated that Tet2 deficiency prevents the interaction between estrogen-receptor alpha and histone H3 controlling epigenetic regulation in mouse macrophages.

Conclusions: Females with TET2 CHIP have accentuated CAD risk and IL-1β blockade limits Tet2-augmented atherosclerosis in female but not male mice. These results highlight the importance of study of sex as a biological variable, uncover a new mechanism of Tet2 CHIP on acceleration of atherosclerosis, and inform the design of trials refining allocation of anti-inflammatory therapies in TET2 CHIP.
  • Vromman, Amelie  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Uddin, Md Mesbah  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Cho, So Mi  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Xue, Liying  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Honigberg, Michael  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Paruchuri, Kaavya  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Koyama, Satoshi  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Zou, Roger  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Ganesh, Shriienidhie  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Zekavat, Seyedeh  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Vlasschaert, Caitlyn  ( Queen's University , Kingston , Ontario , Canada )
  • Nakao, Tetsushi  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Sellar, Rob  ( UCL Cancer Institute , London , United Kingdom )
  • Mcconkey, Marie  ( Dana-Farber Cancer Institute , Boston , Massachusetts , United States )
  • Yu, Zhi  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Tesmenitsky, Yevgenia  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Sausen, Grasiele  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Shvartz, Eugenia  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Wong, Waihay  ( Dana-Farber Cancer Institute , Boston , Massachusetts , United States )
  • Ruvkun, Victoria  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Folco, Eduardo  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Sukhova, Galina  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Fang, Shi  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Bick, Alexander  ( Vanderbilt University Medical Cente , Nashville , Tennessee , United States )
  • Ebert, Benjamin  ( Dana-Farber Cancer Institute , Boston , Massachusetts , United States )
  • Gupta, Rajat  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Natarajan, Pradeep  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Libby, Peter  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Dreyfuss, Jonathan  ( Joslin Diabetes Center , Boston , Massachusetts , United States )
  • Pan, Hui  ( Joslin Diabetes Center , Boston , Massachusetts , United States )
  • Vellarikkal, Shamsudheen  ( The Broad Institute , Cambridge , Massachusetts , United States )
  • Janini Gomes, Mariana  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Carter, Paul  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Moscavitch, Samuel  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Amelie Vromman: DO NOT have relevant financial relationships | Md Mesbah Uddin: DO NOT have relevant financial relationships | So Mi Cho: DO NOT have relevant financial relationships | Liying Xue: DO NOT have relevant financial relationships | Michael Honigberg: DO have relevant financial relationships ; Advisor:Miga Health:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Expected (by end of conference) ; Consultant:Comanche Biopharma:Past (completed) ; Research Funding (PI or named investigator):Genentech:Active (exists now) | Kaavya Paruchuri: No Answer | Satoshi Koyama: DO NOT have relevant financial relationships | Roger Zou: No Answer | Shriienidhie Ganesh: DO NOT have relevant financial relationships | Seyedeh Zekavat: No Answer | Caitlyn Vlasschaert: DO NOT have relevant financial relationships | Tetsushi Nakao: DO NOT have relevant financial relationships | Rob Sellar: DO NOT have relevant financial relationships | Marie McConkey: DO NOT have relevant financial relationships | Zhi Yu: DO NOT have relevant financial relationships | Yevgenia Tesmenitsky: No Answer | Grasiele Sausen: No Answer | Eugenia Shvartz: No Answer | Waihay Wong: No Answer | Victoria Ruvkun: DO NOT have relevant financial relationships | Eduardo Folco: No Answer | Galina Sukhova: No Answer | Shi Fang: DO NOT have relevant financial relationships | Alexander Bick: DO NOT have relevant financial relationships | Benjamin Ebert: No Answer | Rajat Gupta: DO NOT have relevant financial relationships | Pradeep Natarajan: DO have relevant financial relationships ; Researcher:Allelica:Active (exists now) ; Advisor:Preciseli:Active (exists now) ; Advisor:MyOme:Active (exists now) ; Advisor:Esperion Therapeutics:Active (exists now) ; Advisor:TenSixteen Bio:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Genentech / Roche:Active (exists now) ; Consultant:Eli Lilly & Co:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Genentech / Roche:Active (exists now) | Peter Libby: DO have relevant financial relationships ; Consultant:Amgen, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Novo Nordisk, Novartis, and Sanofi-Regeneron:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech:Active (exists now) ; Advisor:AmAmgen, Caristo Diagnostics, CSL Behring, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc.:Active (exists now) | Jonathan Dreyfuss: DO NOT have relevant financial relationships | Hui Pan: DO NOT have relevant financial relationships | Shamsudheen Vellarikkal: No Answer | Mariana Janini Gomes: No Answer | Paul Carter: DO NOT have relevant financial relationships | Samuel Moscavitch: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Mechanisms in Atherosclerosis

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A Novel H2 Relaxin B-Chain-Only Peptide Variant B7-33 Improves The Pathophysiology Of Placental Ischemia In The Reduced Uterine Perfusion Pressure Rat Model Of Preeclampsia

Pantho Ahmed F, Hossain Mohammed, Uddin Mohammad, Amaral Lorena, Campbell Nathan, Afroze Syeda, Vora Niraj, Kuehl Thomas, Lindheim Steven, Lamarca Babbette, Bathgate Ross

Acute intracranial stenting among patients with large vessel occlusion: Clinical and radiological outcomes of the RESISTANT International registry

Requena Manuel, Lopez-frias Alfonso, Hassan Ameer, Miller Samantha, Zapata-arriaza Elena, De Alboniga-chindurza Asier, Bergui Mauro, Molinaro Stefano, Sousa Joao Andre, Gomes Fábio, Alexandre Andrea, Olive-gadea Marta, Pedicelli Alessandro, Hofmeister Jeremy, Machi Paolo, Scarcia Luca, Kalsoum Erwah, Meira Torcato, Amorim José, Ortega-gutierrez Santiago, Rodriguez Aaron, Capasso Francesco, Kaesmacher Johannes, Renieri Leonardo, Romano Daniele, Barcena Eduardo, Abdalkader Mohamad, Perry Da Camara Catarina, Yavagal Dileep, Vega Pedro, Ozdemir Atilla Ozcan, Smajda Stanislas, Khalife Jane, Mujanovic Adnan, Biraschi Francesco, Castro Pedro, Siddiqui Adnan, Navia Pedro, Ntoulias Nikolaos, Velo Mariano, Zamarro Joaquin, Zaidat Osama, Sierra-gomez Alicia, Marto Joao Pedro, Geyik Serdar, Tomasello Alejandro, Senadim Songul, Cervo Amedeo, Salcuni Andrea, Moreu Manuel

More abstracts from these authors:
Dnmt3a modifies the anti-inflammatory effect of the IL-6 classical pathway in macrophages to change the atherosclerosis burden.

Nakao Tetsushi, Sausen Grasiele, Shvartz Eugenia, Folco Eduardo, Ebert Benjamin, Libby Peter, Rentz Thiago, Mcconkey Marie, Williams Jason, Chen Mengyu, Vromman Amelie, Janini Gomes Mariana, Moscavitch Samuel, Tobar Santiago

Genomic, Phenomic, and Geographic Relationships with Leukocyte Telomere Length in the U.S. Yields New Insights for Neoplasms and Cardiometabolic Disease

Nakao Tetsushi, Samani Nilesh, Hornsby Whitney, Ellinor Patrick, Natarajan Pradeep, Koyama Satoshi, Truong Buu, Uddin Md Mesbah, Misra Anika, Patel Aniruddh, Vlasschaert Caitlyn, Bick Alexander, Codd Veryan

You have to be authorized to contact abstract author. Please, Login
Not Available